首页 | 本学科首页   官方微博 | 高级检索  
检索        


Durable immunogenicity,adaptation to emerging variants,and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
Institution:1. Grousbeck Gene Therapy Center, Schepens Eye Research Institute, Mass Eye and Ear, Boston, MA 02114, USA;2. Ocular Genomics Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA 02114, USA;3. The Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA;4. Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA;5. Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IMVA-HB/IDMIT), Université Paris-Saclay, Inserm, CEA, 92260 Fontenay-aux-Roses, France;6. Généthon INTEGRARE UMR-S951 (Institut National de la Santé et de la Recherche Médicale, Université d''Evry, Université Paris-Saclay), 91000 Evry, France;7. KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute, Translational Platform Virology and Chemotherapy (TPVC), 3000 Leuven, Belgium;8. VisMederi Srl, 53100 Siena, Italy;9. University of Siena, Department of Molecular Medicine, 53100 Siena, Italy;10. Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Abstract:
><ol class=
  • Download : Download high-res image (97KB)
  • Download : Download full-size image
  • Keywords:COVID-19  SARS-CoV-2  vaccine  preventative vaccine  genetic vaccine  adeno-associated virus  AAV  durability  single dose  non-human primate  cynomolgus macaque
    本文献已被 ScienceDirect 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号